Combination Therapy of Senaparib and Bevacizumab for First-line Maintenance Therapy in Newly Diagnosed Advanced Homologous Recombination Proficient Ovarian Cancer Based on Exosome Protein Marker

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 10, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2028

Conditions

Advanced Ovarian Cancer

Interventions

DRUG

Senaparib

100mg qd

DRUG

Bevacizumab

7.5mg/kg q3w

Trial Locations (1)

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER